Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Depreciation & Amortization - Total (2019 - 2025)

InMed Pharmaceuticals has reported Depreciation & Amortization - Total over the past 4 years, most recently at $12206.0 for Q2 2025.

  • For Q2 2025, Depreciation & Amortization - Total rose 124.37% year-over-year to $12206.0; the TTM value through Dec 2025 reached $24409.0, down 46.3%, while the annual FY2025 figure was $50204.0, 5.16% up from the prior year.
  • Depreciation & Amortization - Total for Q2 2025 was $12206.0 at InMed Pharmaceuticals, roughly flat from $12203.0 in the prior quarter.
  • Over five years, Depreciation & Amortization - Total peaked at $14242.0 in Q4 2023 and troughed at $5440.0 in Q2 2024.
  • A 4-year average of $11773.0 and a median of $12209.0 in 2024 define the central range for Depreciation & Amortization - Total.
  • Biggest five-year swings in Depreciation & Amortization - Total: tumbled 57.88% in 2024 and later soared 124.37% in 2025.
  • Year by year, Depreciation & Amortization - Total stood at $8056.0 in 2022, then skyrocketed by 76.79% to $14242.0 in 2023, then dropped by 14.27% to $12209.0 in 2024, then dropped by 0.02% to $12206.0 in 2025.
  • Business Quant data shows Depreciation & Amortization - Total for INM at $12206.0 in Q2 2025, $12203.0 in Q1 2025, and $12209.0 in Q4 2024.